We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 42

Increased European patent protection following a landmark ruling on supplementary protection certificates

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • August 30 2012

The Court of Justice of the European Union (CJEU) rendered judgment relating to a preliminary reference from the English Court of Appeal, holding that the existence of an earlier marketing authorization (MA) of a pharmaceutical product does not preclude the grant of a Supplementary Protection Certificate (SPC) for a different application of the same product

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • January 9 2013

In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge

What did you say? $31 million awarded for infringement of hearing aid patent

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

Why life science patents are a breed apart

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • April 10 2007

Patents are creatures of statute. Once an applicant has disclosed an invention, and subject to the application meeting certain statutory standards as to form and content, the European Patent Office grants a 20-year “monopoly”

Pharmaceutical sector under European Commission scanner

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • February 28 2008

The European Commission has begun an investigation into the European pharmaceutical industry

Product and disease registries: planning for data protection

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • April 10 2007

Biopharmaceutical companies have now seen the power of post-market approval and observational registries

Navigating the evolving regulation and commercialization of stem cell research

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage

EMEA and FDA focus on clinical research safety and enforcement

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • August 20 2009

Recent policy changes emphasize the need for sponsoring organizations to be even more vigilant in establishing, updating and monitoring their systems for compliance with clinical research requirements, whether conducted domestically or in a foreign locale

EPO Enlarged Board of Appeal invites the public to determine whether stem cells are contrary to morality

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • July 30 2008

On 24 and 25 June 2008, in a public hearing on Wisconsin Alumni Research Foundation (WARF) Stem Cell patent application (G-0206), the European Patent Office (EPO) took the usual step of asking the public to assist it in making a determination regarding a patent application involving an invention in the controversial area of stem cell patenting

Commission investigates pharmaceutical sector for anti-competitive practices

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • January 18 2008

The European Commission has launched a sector inquiry with a series of on-the-spot competition investigations into pharmaceutical companies

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy